Valuation: Roche Holding AG

Market Cap 291B 358B 311B 266B 502B 34,111B 509B 3,404B 1,336B 17,043B 1,344B 1,315B 56,725B P/E 2026 *
20.3x
P/E 2027 * 18x
Enterprise Value 302B 371B 322B 276B 521B 35,370B 528B 3,530B 1,385B 17,672B 1,394B 1,364B 58,820B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 4.5x
Free-Float
88.78%
Yield 2026 *
2.74%
Yield 2027 * 2.8%
1 day-0.43%
1 week-0.86%
Current month+2.73%
1 month+6.41%
3 months+12.66%
6 months+0.60%
Current year+9.90%
1 week 357
Extreme 357
374.8
1 month 330
Extreme 330
375.8
Current year 301.2
Extreme 301.2
383
1 year 256.4
Extreme 256.4
383
3 years 229.4
Extreme 229.4
383
5 years 229.4
Extreme 229.4
439.2
10 years 209.4
Extreme 209.4
439.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-0.86% - - 361B
+1.89%-1.49%+55.62%+165.18% 1,043B
-0.24%-3.22%+50.51%+52.02% 621B
-0.95%-7.38%+22.83%+65.08% 435B
0.00%+0.83%+42.80%+37.60% 361B
+0.58%-3.51%+31.12%+40.54% 293B
-1.55%-9.78%+5.61%+8.62% 251B
-0.73%+4.44%+34.91%+66.41% 220B
-0.24%-13.15%-4.02%-44.69% 201B
-0.68%-1.41%+16.36%+66.32% 164B
Average -0.51%-3.81%+28.42%+50.79% 398.79B
Weighted average by Cap. -0.53%-3.79%+37.57%+77.18%

Financials

2026 *2027 *
Net sales 62.64B 77.09B 66.9B 57.3B 108B 7,344B 110B 733B 288B 3,669B 289B 283B 12,213B 65.47B 80.57B 69.92B 59.89B 113B 7,675B 115B 766B 301B 3,835B 303B 296B 12,764B
Net income 14.51B 17.85B 15.49B 13.27B 25.05B 1,701B 25.38B 170B 66.6B 850B 67.03B 65.57B 2,828B 16.33B 20.1B 17.44B 14.94B 28.2B 1,915B 28.57B 191B 74.99B 957B 75.46B 73.82B 3,184B
Net Debt 10.74B 13.22B 11.47B 9.83B 18.56B 1,260B 18.8B 126B 49.33B 629B 49.65B 48.57B 2,095B 3.96B 4.88B 4.23B 3.63B 6.84B 465B 6.93B 46.36B 18.2B 232B 18.31B 17.91B 773B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-08-06 CHF 368.40 -0.43% 13,560
26-08-05 CHF 370.00 +1.87% 17,093
26-08-04 CHF 363.20 +0.89% 21,569
26-08-03 CHF 360.00 +0.39% 23,285
26-07-31 CHF 358.60 -0.06% 16,398
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
364.70CHF
Average target price
363.92CHF
Spread / Average Target
-0.21%

Quarterly revenue - Rate of surprise